Inotek Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA and Phase 3 Development Strategy for Trabodenoson, a Novel Treatment for Glaucoma
July 23, 2015 at 07:10 AM EDT
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today announced the Phase 3 development strategy of its lead ...